Charles River Labs Appoints Glenn Coleman as New CFO

summarizeSummary

Charles River Laboratories announced the appointment of Glenn Coleman as its new Chief Financial Officer, bringing extensive experience from previous CFO roles in the healthcare sector.

check_boxKey Events

• New CFO Appointed

  Glenn Coleman has been appointed Corporate Executive Vice President and Chief Financial Officer, with a tentative start date of April 6, 2026.

• Experienced Financial Leader

  Mr. Coleman has over 30 years of financial and operational management experience, including serving as CFO for Premier, DENTSPLY SIRONA Inc., and Integra Life Sciences Holdings Corporation.

• Substantial Compensation Package

  His compensation includes an $800,000 annual base salary, an 85% target bonus, a $3,000,000 annual equity award, a one-time $1,875,000 cash award, and a one-time $3,500,000 new hire equity award.

• Succession from Interim Role

  Mr. Coleman will succeed Michael G. Knell, who served as interim CFO since September 2025 and will continue as Corporate Senior Vice President and Chief Accounting Officer.

auto_awesomeAnalysis

Charles River Laboratories has appointed Glenn Coleman as its new Corporate Executive Vice President and Chief Financial Officer, a critical leadership change following recent financial disclosures. Mr. Coleman brings over 30 years of extensive financial and operational management experience, including prior CFO roles at other public healthcare companies like Premier, DENTSPLY SIRONA, and Integra Life Sciences. This appointment signals the company's commitment to strengthening its financial leadership, particularly after reporting a net loss and significant non-cash impairments for fiscal year 2025. His deep industry experience and proven track record are expected to be instrumental in navigating future financial strategies and operational efficiencies.